{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:09:17Z","timestamp":1775797757801,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ovarian cancer remains one of the leading causes of gynecologic cancer mortality worldwide, largely due to late-stage diagnosis and high recurrence rates. Mutations in the BRCA1 and BRCA2 genes disrupt homologous recombination repair pathways, creating a therapeutic vulnerability that can be exploited by poly (ADP-ribose) polymerase (PARP) inhibitors. Although PARP inhibitors have demonstrated clinical benefits in BRCA-mutated ovarian cancer, variability across clinical studies has led to uncertainty regarding their overall effectiveness and long-term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to systematically evaluate the efficacy and safety of PARP inhibitor\u2013based therapy in patients with BRCA-mutated ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review and meta-analysis were conducted following PRISMA 2020 guidelines. Four electronic databases (PubMed, Scopus, EMBASE, and Cochrane Library) were searched for studies published between 2013 and 2025. Eligible studies included randomized controlled trials and observational cohort studies evaluating PARP inhibitors in patients with BRCA-mutated ovarian cancer. Risk of bias was assessed using the Cochrane Risk of Bias Tool and the Newcastle\u2013Ottawa Scale. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a meta-analytic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve studies met the inclusion criteria for qualitative synthesis, including five randomized controlled trials and seven observational cohort studies. Four studies were eligible for quantitative meta-analysis. PARP inhibitor therapy significantly improved progression-free survival (PFS) (HR: 0.62, 95% CI: 0.56\u20130.68). In contrast, improvement in overall survival (OS) was modest (HR: 0.82, 95% CI: 0.68\u20130.98) and less consistently reported. Hematologic toxicities, particularly anemia and thrombocytopenia, were the most frequently reported grade \u22653 adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PARP inhibitors provide a significant progression-free survival benefit in patients with BRCA-mutated ovarian cancer, particularly when used as maintenance therapy. However, the impact on overall survival remains uncertain, highlighting the need for longer follow-up and further prospective studies to optimize treatment strategies and clarify long-term clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1778168","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:27:29Z","timestamp":1775795249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer: systematic literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Dwi Andhika","family":"Panjarwanto","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Brawijaya University","place":["Malang, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Putri","family":"Nabila","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Pelita Harapan University","place":["Tangerang, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leony","family":"Octavia","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hasanuddin University","place":["Makassar, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I Wayan Agung","family":"Indrawan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine Brawijaya University\/dr Saiful Anwar Hospital","place":["Malang, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudi Priyo","family":"Utomo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine Brawijaya University\/dr Saiful Anwar Hospital","place":["Malang, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adin Yan","family":"Permana","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine Brawijaya University\/dr Saiful Anwar Hospital","place":["Malang, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Kaspan","sequence":"additional","affiliation":[{"name":"Department Obstetrics and Gynecology, Patut Patuh Patju Hospital","place":["West Gerung, West Nusa Tenggara, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I Gde Hary Eka","family":"Adnyana","sequence":"additional","affiliation":[{"name":"Department Obstetrics and Gynecology, Patut Patuh Patju Hospital","place":["West Gerung, West Nusa Tenggara, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Mohamad","family":"Javier","sequence":"additional","affiliation":[{"name":"Division of Critical Care Unit, Department of Cardiology & Vascular Medicine, National Cardiovascular Center of Harapan Kita","place":["Jakarta, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Zidan Habibullah","family":"Akbar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Islam Sultan Agung","place":["Semarang, Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0143-5","article-title":"The clinicopathological significance of mir-1307 in chemotherapy resistant epithelial ovarian cancer","volume":"8","author":"Zhou","year":"2015","journal-title":"J Ovarian Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-6-7","article-title":"Prima-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for akt down-regulation","volume":"6","author":"Kobayashi","year":"2013","journal-title":"J Ovarian Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14046624","article-title":"Regulation of ovarian cancer stem cells or tumor-initiating cells","volume":"14","author":"Kwon","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/mp4005244","article-title":"Ultrasound-mediated destruction of lhrha-targeted and paclitaxel-loaded lipid microbubbles induces proliferation inhibition and apoptosis in ovarian cancer cells","volume":"11","author":"Liu","year":"2013","journal-title":"Mol Pharmaceutics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087455","article-title":"Inhibition of hdac1 and dnmt1 modulate rgs10 expression and decrease ovarian cancer chemoresistance","volume":"9","author":"\u00c7a\u00e7an","year":"2014","journal-title":"PloS One"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/srep04026","article-title":"Clinical characteristics of ovarian cancer classified by brca1, brca2 and rad51c status","volume":"4","author":"Cunningham","year":"2014","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4361","article-title":"Genome-wide transcriptome profiling of homologous recombination dna repair","volume":"5","author":"Peng","year":"2014","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21522","article-title":"Comprehensive mutation profiling by next\u2010generation sequencing of effusion fluids from patients with high\u2010grade serous ovarian carcinoma","volume":"123","author":"Shah","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ijc.29829","article-title":"Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas","volume":"138","author":"Mani\u00e9","year":"2015","journal-title":"Int J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201201823","article-title":"Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer","volume":"5","author":"Tan","year":"2013","journal-title":"EMBO Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3748","article-title":"New parp targets for cancer therapy","volume":"14","author":"Vyas","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-0088","article-title":"Development of olaparib for brca-deficient recurrent epithelial ovarian cancer","volume":"21","author":"Tewari","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.394","article-title":"The development of parp inhibitors in ovarian cancer: from bench to bedside","volume":"113","author":"Drew","year":"2015","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-12-0813","article-title":"Therapeutic potential of the poly(adp-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer","volume":"12","author":"Ihnen","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/pgpm.s62809","article-title":"Olaparib in the management of ovarian cancer","author":"Bixel","year":"2015","journal-title":"Pharmacogenom. Pers Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.05.009","article-title":"An ex vivo assay of xrt-induced rad51 foci formation predicts response to parp-inhibition in ovarian cancer","volume":"134","author":"Shah","year":"2014","journal-title":"Gynecol. Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.8848","article-title":"Poly (adp-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.392","article-title":"Parp inhibitors in ovarian cancer","volume":"113","author":"Cibula","year":"2015","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.395","article-title":"Parp inhibitors in ovarian cancer: clinical evidence for informed treatment decisions","volume":"113","author":"Ledermann","year":"2015","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline brca1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2565","article-title":"Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or brca-mutant ovarian cancer","volume":"21","author":"Kummar","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2015.1078238","article-title":"Bracanalysis cdx as a companion diagnostic tool for lynparza","volume":"15","author":"Gunderson","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091467","article-title":"Corrected allele frequency of BRCA1\/2 mutations is an independent prognostic factor for treatment response to PARP-inhibitors in ovarian cancer patients","volume":"12","author":"Grech","year":"2022","journal-title":"J Personalized. Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221149136","article-title":"Real-world efficacy and safety of PARP inhibitors in recurrent ovarian cancer patients with somatic BRCA and other homologous recombination gene mutations","volume":"57","author":"Pan","year":"2023","journal-title":"Ann Pharmacother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231173181","article-title":"Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer","volume":"15","author":"Nicoletto","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001219","article-title":"PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer","volume":"32","author":"Rose","year":"2021","journal-title":"Anti-Cancer. Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1078-0432.ccr-22-3715","article-title":"Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-611","article-title":"Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition","volume":"75","author":"Dougherty","year":"2015","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.11.037","article-title":"Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer","volume":"181","author":"Kim","year":"2023","journal-title":"Gynecol. Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11684-024-1083-5","article-title":"First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive\/BRCA wild-type ovarian cancer: real-world multicenter study","author":"Li","year":"2024","journal-title":"Front Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1225","article-title":"Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1\/2 and a scar-based HRD signature in real-world practice","author":"Richardson","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ygyno.2023.06.127","article-title":"Evaluating the real-world impact of first line PARP inhibitor maintenance therapy in patients with BRCA mutated ovarian tumors","volume":"176","author":"Piedimonte","year":"2023","journal-title":"Gynecol. Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000793","article-title":"Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Anti-Cancer. Drugs"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0594","article-title":"Parp inhibition induces enrichment of DNA repair\u2013proficient CD133 and CD117 positive ovarian cancer stem cells","volume":"17","author":"Bellio","year":"2019","journal-title":"Mol Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1778168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:27:29Z","timestamp":1775795249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1778168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1778168"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1778168","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1778168"}}